Table 2 Baseline characteristics of the unpaired cross-sectional study

From: The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy

  No-statin-No-PCSK9 group Statin group PCSK9 group P-value
  (n = 41) (n = 60) (n = 19)
Mean age (year) 64.6 ± 10.7 65.7 ± 5.0 64.1 ± 7.9 0.7738
Male sex (%) 51 65 32 0.0310
BMI (kg/m2) 24.0 ± 4.3 24.8 ± 3.6 24.2 ± 2.7 0.6065
Rate of hypertension treatment (%) 27 30 26 0.9298
Smoking (%) 7 3 0 0.0456
Past history of coronary heart disease (%) 13 39 56 0.0010
Family history of coronary heart disease (%) 20 37 47 0.0572
Systolic bood pressure (mmHg) 135 (91–170) 134 (90–168) 141 (94–164) 0.9201
Diastolic bood pressure (mmHg) 84 (60–100) 83 (59–99) 86 (58–98) 0.9104
Plasma glucose (mg/dL) 124.3 ± 41.0 127.8 ± 41.7 121.0 ± 28.6 0.8200
Hemoglobin A1c (%) 6.14 ± 0.94 6.28 ± 0.81 6.09 ± 0.80 0.7218
Total cholesterol (mg/dL) 201.2 ± 57.5 178.4 ± 46.5 176.7 ± 46.4 0.1829
Triglyceride (mg/dL) 163.8 ± 99.5 192.7 ± 237.4 188.1 ± 96.0 0.7974
High density lipoprotein-cholesterol (mg/dL) 54.7 ± 13.3 54.7 ± 12.4 58.7 ± 12.8 0.5125
Low density lipoprotein-cholesterol (mg/dL) 114.8 ± 53.7 91.4 ± 37.9 79.2 ± 41.6 0.0213
Lp(a) (mg/dL) 7.8 ± 9.7 22.4 ± 22.6 26.0 ± 33.1 0.4678
  1. Data were average ± standard deviation or median (range of 10th–90th percentile)